Scholarlink

Background <p>Migraine remains a significant global burden, necessitating effective non-pharmacological alternatives. Magnesium plays a critical role in migraine pathophysiology through NMDA receptor blockade, neurotransmitter regulation, and the inhibition of cortical spreading depression. However, clinical data remain contradictory, particularly regarding the efficacy of various magnesium salts.</p> Objective <p>This systematic review evaluates the efficacy and safety of oral magnesium supplementation compared to placebo or standard care (sodium valproate) for migraine prophylaxis.</p> Methods <p>We analyzed randomized, double-blind trials and crossover studies involving diverse populations in Germany, Iran, Italy, and Turkey. Interventions included daily doses of 360–600&#xa0;mg across multiple formulations: magnesium dicitrate, oxide, aspartate, and pyrrolidone carboxylic acid.</p> Results <p>Efficacy varied significantly by formulation. Trimagnesium dicitrate (600&#xa0;mg/day) significantly reduced attack frequency and severity compared to placebo (<i>p</i> &lt; 0.05). Conversely, magnesium aspartate failed to demonstrate superiority over placebo, necessitating early study discontinuation. In active-comparator trials, 500&#xa0;mg of magnesium oxide demonstrated efficacy similar to sodium valproate. Furthermore, concurrent magnesium and valproate therapy significantly outperformed valproate monotherapy. The most common adverse effects were gastrointestinal, including diarrhea (up to 18.6%) and soft stools.</p> Conclusion <p>Oral magnesium, particularly in citrate or oxide forms at 500–600&#xa0;mg daily, is an effective and safe prophylactic option. While gastrointestinal side effects may limit adherence, magnesium remains a viable alternative or adjunct to standard pharmacological treatments.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of magnesium supplementation in the prophylaxis of migraine: a systematic review of clinical trials comparing oral magnesium to placebo or standard care

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月7日

查看全文
  • Habiblah Jagunmolu,
  • Emmanuel Oyetola,
  • Yusuff Lawal,
  • Samuel Oyelude,
  • Oluwatomisin Ogunsola,
  • Abdulmujeeb Oladeji,
  • Salahudeen Ogundipe,
  • Mukhtar Ibrahim,
  • Dhikrat Ajibade,
  • Oluwadamilola Ariyo,
  • Kamil Ajagbe

摘要

Background

Migraine remains a significant global burden, necessitating effective non-pharmacological alternatives. Magnesium plays a critical role in migraine pathophysiology through NMDA receptor blockade, neurotransmitter regulation, and the inhibition of cortical spreading depression. However, clinical data remain contradictory, particularly regarding the efficacy of various magnesium salts.

Objective

This systematic review evaluates the efficacy and safety of oral magnesium supplementation compared to placebo or standard care (sodium valproate) for migraine prophylaxis.

Methods

We analyzed randomized, double-blind trials and crossover studies involving diverse populations in Germany, Iran, Italy, and Turkey. Interventions included daily doses of 360–600 mg across multiple formulations: magnesium dicitrate, oxide, aspartate, and pyrrolidone carboxylic acid.

Results

Efficacy varied significantly by formulation. Trimagnesium dicitrate (600 mg/day) significantly reduced attack frequency and severity compared to placebo (p < 0.05). Conversely, magnesium aspartate failed to demonstrate superiority over placebo, necessitating early study discontinuation. In active-comparator trials, 500 mg of magnesium oxide demonstrated efficacy similar to sodium valproate. Furthermore, concurrent magnesium and valproate therapy significantly outperformed valproate monotherapy. The most common adverse effects were gastrointestinal, including diarrhea (up to 18.6%) and soft stools.

Conclusion

Oral magnesium, particularly in citrate or oxide forms at 500–600 mg daily, is an effective and safe prophylactic option. While gastrointestinal side effects may limit adherence, magnesium remains a viable alternative or adjunct to standard pharmacological treatments.